Clinical Trials Browser

Phase 1 × Recurrence × pembrolizumab × Clear all

NCT05359445 2026-04-17

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Phase 1 Active not recruiting

Neoplasms, Recurrence

NCT01822652 2026-04-06

GRAIN

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

NCT07501650 2026-03-30

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Phase 1 Recruiting

Head and Neck Neoplasms, Recurrence

NCT05537740 2026-03-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT02628574 2025-08-03

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Phase 1 Completed

Neoplasm Metastasis, Recurrence

NCT03340766 2024-10-17

HARBOUR

Phase 1 Completed

31 enrolled 29 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Phase 1 Completed

58 enrolled 17 charts

DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT04478695 2024-03-08

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

1 enrolled 2 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03941262 2023-11-13

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT03144245 2021-10-12

Study of AMV564 in Patients With AML

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03605589 2021-04-01

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT04279938 2020-02-21

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Phase 1 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse